Company intelligence / Profile preview

Technovalia

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

COVIGEN, a plasmid-DNA COVID‑19 vaccine developed by Technovalia and BioNet, was the first of its kind tested in Australia. Interim phase 1 results showed it was well tolerated with no safety concerns. The company also participates in booster studies using this candidate. Other programs include a chikungunya prophylactic vaccine at preclinical stage and involvement in clinical evaluation of recombinant acellular pertussis vaccines through partnerships.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccinemRNA-based drugsRecombinant proteinProphylactic vaccine
Industry: Biotech

Drug pipeline

1 asset

COVIGEN

Partnerships

BioNet AsiaSypharmaPharmaJet®The Telethon Kids Institute WAMonash UniversityGenetis (JV)

Beyond the preview

Go deeper on Technovalia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Technovalia.

Explore the full profile